Adial Pharmaceuticals Submits AD04 Application for FDA Priority Program
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Apr 27 2026
0mins
Adial Pharmaceuticals announced the submission of the AD04 product application for consideration of the FDA Commissioner's National Priority Voucher Pilot Program. Announced in 2025, the CNPV program is designed to speed up the FDA review process for drugs that address one of five key U.S. national health priorities. It uses a collaborative review approach-similar to a "tumor board," where experts meet to discuss cases-to help evaluate applications more efficiently.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ADIL?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on ADIL
Wall Street analysts forecast ADIL stock price to fall
1 Analyst Rating
1 Buy
0 Hold
0 Sell
Moderate Buy
Current: 2.750
Low
1.50
Averages
1.50
High
1.50
Current: 2.750
Low
1.50
Averages
1.50
High
1.50
About ADIL
Adial Pharmaceuticals, Inc. is a biopharmaceutical company. Its lead program is AT177, a proprietary colon‑targeted aryl hydrocarbon receptor (AhR) agonist designed to enable localized activation with limited systemic exposure in development for ulcerative colitis. AT177 is a fully synthetic, patented, oral AhR agonist designed to restore mucosal immune homeostasis at the site of disease with minimal systemic exposure. AT177's active ingredient is a prodrug of indirubin, a potent AhR agonist within indigo naturalis, a botanical extract with clinical efficacy in ulcerative colitis. AT177's colon-targeted formulation delivers therapeutic AhR engagement directly to the colonic mucosa with exquisite gut restriction, minimizing the systemic AhR exposure associated with adverse effects. Its historical investigational new drug product, AD04, is a genetically targeted, serotonin-3 receptor antagonist, therapeutic agent for the treatment of Alcohol Use Disorder in heavy drinking patients.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Adial Pharmaceuticals Acquires Azora, Shares Surge Over 35%
- Acquisition Announcement: Adial Pharmaceuticals has announced the acquisition of Azora Therapeutics, gaining its lead asset AT177 for ulcerative colitis treatment, which not only enhances its product portfolio but also potentially boosts its market competitiveness.
- Financing Deal: Concurrently, the company entered a $64 million private placement, including $32 million in upfront financing for pre-funded warrants to purchase 11,780,948 shares, reflecting investor confidence in its future growth prospects.
- Clinical Trial Plans: AT177, designed as a colon-targeted drug, is set to initiate proof-of-concept clinical studies in 2027, with a potential $32 million milestone payment upon trial initiation, further advancing its research and development efforts.
- Stock Price Movement: Following the announcement, Adial's shares surged over 35%, closing at $2.98, although they fell 14.38% in pre-market trading, indicating a mixed but generally positive market reaction to the acquisition and financing news.
See More
Biotech Companies See Significant Stock Gains
- Gelteq Stock Surge: Australia-based Gelteq's shares soared over 197% without specific news, as the company commenced its first clinical trial for an antiparasitic drug candidate, which is expected to drive an FDA submission and enhance market competitiveness.
- Adial Acquires Azora: Adial Pharmaceuticals announced the acquisition of Azora Therapeutics with up to $64 million in financing, which will strengthen its pipeline for treating serious inflammatory diseases, with a Phase I clinical trial planned for 2027 expected to create new growth opportunities.
- Precigen Commercial Momentum: Precigen's PAPZIMEOS sales reached $21.6 million in Q1 2026, a significant increase from $3.4 million in Q4 2025, indicating strong commercialization momentum in the U.S. market, with expectations for further market share expansion.
- Eloxx Nasdaq Uplisting: Eloxx Pharmaceuticals' stock rose over 14% following its uplisting to Nasdaq, with plans to initiate a Phase 2b clinical trial for its lead drug Exaluren targeting Alport syndrome in Q3 2026, which is expected to provide new growth opportunities for the company.
See More
Adial Pharmaceuticals Acquires Azora Therapeutics to Enhance Pipeline
- Acquisition Announcement: Adial Pharmaceuticals has acquired Azora Therapeutics, gaining its lead asset AT177, a colon-targeted drug for inflammatory diseases, which is expected to significantly enhance the company's pipeline and drive future growth.
- Financing Agreement: The company entered into a $64 million private placement agreement, with $32 million available at closing and an additional $32 million tied to the initiation of Phase 1 trials, reflecting strong investor confidence in the project.
- Use of Proceeds: The proceeds will primarily be used to advance AT177 through IND-enabling work and Phase 1a/1b studies in ulcerative colitis, aiming to accelerate product development and meet market demand, thereby enhancing the company's competitiveness in the biopharma sector.
- New Board Member: Adial Pharmaceuticals appointed Dr. Wendy Young to its Board of Directors, bringing over 32 years of drug discovery and biopharma leadership experience, which is expected to provide significant support for the company's strategic development and technological innovation.
See More
Adial's Acquisition of Azora Boosts Stock Price by 110%
- Transaction Overview: Adial Pharmaceuticals' acquisition of Azora Therapeutics aims to integrate its lead drug candidate AT177 into Adial's pipeline, with the first human clinical trial expected to commence in mid-2027, marking a strategic shift from addiction treatments to inflammatory diseases.
- Financing Strategy: The deal is accompanied by up to $64 million in private financing, with $32 million to be invested immediately and the remaining $32 million contingent on the successful initiation of AT177's first human clinical trial, primarily funding its development and early-stage clinical studies.
- Shareholder Structure Changes: Post-transaction, Azora shareholders will own approximately 51% of the combined entity, existing Adial shareholders about 8%, and new investors around 41%, indicating strong support for the new business direction.
- Market Reaction: Adial's stock surged by 110% following the announcement, potentially marking its best day since September 2020, although retail sentiment shifted from 'neutral' to 'bearish'; nonetheless, analysts maintain a 'Buy' rating with a 12-month price target of $25, suggesting over 1000% upside potential.
See More
Adial Pharmaceuticals Reports Q1 2026 Business Update and Financial Results
- Regulatory Policy Favor: Recent FDA discussions indicate that drug approval may only require one adequate and well-controlled study along with confirmatory evidence in scientifically justified cases, potentially significantly reducing AD04's development costs and accelerating the NDA submission timeline, thereby enhancing the company's capital efficiency.
- New Clinical Trial Direction: With increasing bipartisan support for patient-centered clinical trial endpoints, the development direction of AD04 aligns with new legislation emphasizing clinically meaningful improvements such as reductions in heavy drinking and overall disease severity, further validating its potential as a precision medicine treatment for AUD.
- Strategic Partnership Formation: Adial has established a collaboration framework with Molteni Farmaceutici, marking an important first step toward building a commercial pathway for AD04 in Europe, where Molteni's expertise in addiction therapeutics will support AD04's global expansion.
- Financial Overview: As of March 31, 2026, Adial reported cash and cash equivalents of $4.6 million, expected to fund operations into the second half of 2026, while R&D expenses decreased by 42% year-over-year, demonstrating the company's effectiveness in cost control.
See More
Adial Files Patent Application for AD04 to Enhance Market Competitiveness
- Patent Application Progress: Adial Pharmaceuticals has filed a new patent application for its lead investigational drug AD04, aimed at protecting its core assets until 2045, which is expected to significantly enhance the company's market competitiveness.
- Prioritized Examination Request: The application includes a request for Track One Prioritized examination to shorten the review time, allowing the company to gain earlier insights into patentability, thereby optimizing its strategic planning and improving market responsiveness.
- Enhanced Commercialization Potential: If granted, the patent will provide legal protection for AD04's commercialization, increasing its attractiveness in potential partnership negotiations and enhancing the overall value proposition of the company.
- Multiple Indication Prospects: Beyond Alcohol Use Disorder, AD04 is believed to have the potential to treat other addictive disorders such as Opioid Use Disorder, gambling, and obesity, further expanding the company's market opportunities.
See More
Adial Pharmaceuticals Acquires Azora, Shares Surge Over 35%
- Acquisition Announcement: Adial Pharmaceuticals has announced the acquisition of Azora Therapeutics, gaining its lead asset AT177 for ulcerative colitis treatment, which not only enhances its product portfolio but also potentially boosts its market competitiveness.
- Financing Deal: Concurrently, the company entered a $64 million private placement, including $32 million in upfront financing for pre-funded warrants to purchase 11,780,948 shares, reflecting investor confidence in its future growth prospects.
- Clinical Trial Plans: AT177, designed as a colon-targeted drug, is set to initiate proof-of-concept clinical studies in 2027, with a potential $32 million milestone payment upon trial initiation, further advancing its research and development efforts.
- Stock Price Movement: Following the announcement, Adial's shares surged over 35%, closing at $2.98, although they fell 14.38% in pre-market trading, indicating a mixed but generally positive market reaction to the acquisition and financing news.
See More
Biotech Companies See Significant Stock Gains
- Gelteq Stock Surge: Australia-based Gelteq's shares soared over 197% without specific news, as the company commenced its first clinical trial for an antiparasitic drug candidate, which is expected to drive an FDA submission and enhance market competitiveness.
- Adial Acquires Azora: Adial Pharmaceuticals announced the acquisition of Azora Therapeutics with up to $64 million in financing, which will strengthen its pipeline for treating serious inflammatory diseases, with a Phase I clinical trial planned for 2027 expected to create new growth opportunities.
- Precigen Commercial Momentum: Precigen's PAPZIMEOS sales reached $21.6 million in Q1 2026, a significant increase from $3.4 million in Q4 2025, indicating strong commercialization momentum in the U.S. market, with expectations for further market share expansion.
- Eloxx Nasdaq Uplisting: Eloxx Pharmaceuticals' stock rose over 14% following its uplisting to Nasdaq, with plans to initiate a Phase 2b clinical trial for its lead drug Exaluren targeting Alport syndrome in Q3 2026, which is expected to provide new growth opportunities for the company.
See More
Adial Pharmaceuticals Acquires Azora Therapeutics to Enhance Pipeline
- Acquisition Announcement: Adial Pharmaceuticals has acquired Azora Therapeutics, gaining its lead asset AT177, a colon-targeted drug for inflammatory diseases, which is expected to significantly enhance the company's pipeline and drive future growth.
- Financing Agreement: The company entered into a $64 million private placement agreement, with $32 million available at closing and an additional $32 million tied to the initiation of Phase 1 trials, reflecting strong investor confidence in the project.
- Use of Proceeds: The proceeds will primarily be used to advance AT177 through IND-enabling work and Phase 1a/1b studies in ulcerative colitis, aiming to accelerate product development and meet market demand, thereby enhancing the company's competitiveness in the biopharma sector.
- New Board Member: Adial Pharmaceuticals appointed Dr. Wendy Young to its Board of Directors, bringing over 32 years of drug discovery and biopharma leadership experience, which is expected to provide significant support for the company's strategic development and technological innovation.
See More
Adial's Acquisition of Azora Boosts Stock Price by 110%
- Transaction Overview: Adial Pharmaceuticals' acquisition of Azora Therapeutics aims to integrate its lead drug candidate AT177 into Adial's pipeline, with the first human clinical trial expected to commence in mid-2027, marking a strategic shift from addiction treatments to inflammatory diseases.
- Financing Strategy: The deal is accompanied by up to $64 million in private financing, with $32 million to be invested immediately and the remaining $32 million contingent on the successful initiation of AT177's first human clinical trial, primarily funding its development and early-stage clinical studies.
- Shareholder Structure Changes: Post-transaction, Azora shareholders will own approximately 51% of the combined entity, existing Adial shareholders about 8%, and new investors around 41%, indicating strong support for the new business direction.
- Market Reaction: Adial's stock surged by 110% following the announcement, potentially marking its best day since September 2020, although retail sentiment shifted from 'neutral' to 'bearish'; nonetheless, analysts maintain a 'Buy' rating with a 12-month price target of $25, suggesting over 1000% upside potential.
See More
Adial Pharmaceuticals Reports Q1 2026 Business Update and Financial Results
- Regulatory Policy Favor: Recent FDA discussions indicate that drug approval may only require one adequate and well-controlled study along with confirmatory evidence in scientifically justified cases, potentially significantly reducing AD04's development costs and accelerating the NDA submission timeline, thereby enhancing the company's capital efficiency.
- New Clinical Trial Direction: With increasing bipartisan support for patient-centered clinical trial endpoints, the development direction of AD04 aligns with new legislation emphasizing clinically meaningful improvements such as reductions in heavy drinking and overall disease severity, further validating its potential as a precision medicine treatment for AUD.
- Strategic Partnership Formation: Adial has established a collaboration framework with Molteni Farmaceutici, marking an important first step toward building a commercial pathway for AD04 in Europe, where Molteni's expertise in addiction therapeutics will support AD04's global expansion.
- Financial Overview: As of March 31, 2026, Adial reported cash and cash equivalents of $4.6 million, expected to fund operations into the second half of 2026, while R&D expenses decreased by 42% year-over-year, demonstrating the company's effectiveness in cost control.
See More
Adial Files Patent Application for AD04 to Enhance Market Competitiveness
- Patent Application Progress: Adial Pharmaceuticals has filed a new patent application for its lead investigational drug AD04, aimed at protecting its core assets until 2045, which is expected to significantly enhance the company's market competitiveness.
- Prioritized Examination Request: The application includes a request for Track One Prioritized examination to shorten the review time, allowing the company to gain earlier insights into patentability, thereby optimizing its strategic planning and improving market responsiveness.
- Enhanced Commercialization Potential: If granted, the patent will provide legal protection for AD04's commercialization, increasing its attractiveness in potential partnership negotiations and enhancing the overall value proposition of the company.
- Multiple Indication Prospects: Beyond Alcohol Use Disorder, AD04 is believed to have the potential to treat other addictive disorders such as Opioid Use Disorder, gambling, and obesity, further expanding the company's market opportunities.
See More
